CNTB - Connect Biopharma to Report First Half 2022 Financial Results on September 13
Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT
SAN DIEGO and TAICANG, SUZHOU, China, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company developing therapeutics for T cell-driven inflammatory diseases, today announced it will report financial results for the six-month period ended June 30, 2022, on Tuesday, September 13, after market close. Following the press release, the Company will host a webcast and conference call at 1:30 p.m. PDT to discuss the financial results and provide a corporate update.
The news release will be posted to the investor relations section of Connect Biopharma’s website at: https://investors.connectbiopharm.com/investors .
- To listen to the live webcast of the conference call, or the replay, which will be available for 12 months, investors can follow this link: https://edge.media-server.com/mmc/p/vftshcme .
- To participate in the live telephone conference call, follow this link to register in advance: Registration Link f o r T eleconference Dial In . Upon registering, you will receive a dial-in number and unique PIN to join the conference call.
About Connect Biopharma Holdings Limited
Connect Biopharma is a U.S. and China-based clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell research. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4R?) in development for the treatment of atopic dermatitis and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, for the treatment of pruritus associated with AD. For more information, please visit: https://www.connectbiopharm.com/ .
IR/PR CONTACTS: Ina McGuinnessT: +1 (805) 427-1372imcguinness@connectpharm.comCorporate Contacts:info@connectpharm.com